01/09/2023

Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023.

BOSTON, September 1, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced multiple presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 being held...

10/05/2023

Chiesi Global Rare Diseases Announces FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease.

Updated August 17, 2023

BOSTON, May 10, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved ELFABRIO (pegunigalsidase alfa-iwxj) in...

05/05/2023

Chiesi Global Rare Diseases Announces European Commission (EC) Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease.

Updated August 17, 2023

PARMA, Italy and BOSTON, May 5, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that the European Commission (EC) has granted marketing authorization to PRX 102 (pegunigalsidase alfa) in the European Union (EU) for the treatment of...

15/08/2023

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders.

BOSTON, August 15, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced a co-development agreement with...

18/04/2023

Chiesi Global Rare Diseases Announces U.S. Networkwide Sponsorship of BioInnovation Labs.

BOSTON, April 18, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced a U.S. Networkwide Sponsorship of BioInnovation Labs (BioLabs), the leading developer and operator of life science coworking spaces...

12/04/2023

Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc.

Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. (“Chiesi”), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical...

04/04/2023

Chiesi Global Rare Diseases Announces Collaboration with the National Alliance on Mental Illness to Offer Mental Health Resources for Fabry Disease.

BOSTON, April 4, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced a collaboration with the National Alliance on Mental Illness (NAMI), the nation’s largest ...

24/02/2023

Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19^th Annual WORLDSymposium™ Research Meeting.

BOSTON, February 24, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced the oral presentation of long-term results from the Phase 3 BALANCE and BRIGHT studies...

24/02/2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease.

PARMA/BOSTON and CARMIEL, Israel, February 24, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company, announced today that the European Medicines Agency’s (EMA) Committee for...

16/02/2023

Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis.

BOSTON, February 16, 2023 – Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the U.S. Food and Drug Administration (FDA) has approved Lamzede® (velmanase alfa-tycv) for the treatment of non-neurological manifestations of alpha-mannosidosis (AM) in adult and pediatric patients.
See Boxed Warning - Hypersensitivity Reactions including Anaphylaxis and additional Important Safety Information....

15/02/2023

Chiesi Global Rare Diseases to Present at the 19^th Annual WORLDSymposium™ Research Meeting.

BOSTON, February 15, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that eight abstracts have been accepted for presentation at the 19^th Annual WORLDSymposium™ Research Meeting to be held February 22–26, 2023 in Orlando....